DEVA manufactures pharmaceuticals in four factories; the most expensive room in the profit statement is not on the factory floor. In the first three months of 2026, pay, bonuses, and similar benefits provided to directors and above came to TL 286.7 million. Operating profit for the same period was TL 347.9 million. This comparison is not a profit distribution table, but a ratio between two separate financial statement lines measured against the scale of the company. Even so, it is not a ratio small enough to hide: 82 percent.
The question does not end with whether the executive floor is expensive. On 11 July 2026, the share price of TL 70.65 implied a market capitalization of TL 14.13 billion; equity at 31 March was TL 28.84 billion. The market is assigning 49 kuruş to each lira of DEVA's book value. And even a severe calculation that strips out all intangible assets, one quarter of inventories, and one tenth of trade receivables leaves TL 87.66 of residual value per share.
DEVA is not clean enough to buy on the label of a good company. But neither is it expensive enough to deny its cheapness merely because poor governance leaves a smell in the air. Looking at this share, the task is not to become angry. It is to count how many times the market price has punished the executive floor, the license ledger, and the pharmacy shelf.
Twelve boxes behind 675 products
DEVA in the annual report is broad: more than 675 products across 15 therapeutic areas, 1,863 licenses in 86 countries, exports to more than 60 countries, and annual production capacity of 620 million boxes. DEVA in the financial footnotes is narrower. Human pharmaceuticals generated TL 5.44 billion of first-quarter sales, 92 percent of total sales. The first 12 products carried 50.7 percent of revenue. The two largest pharmaceutical wholesalers accounted for 21 percent and 36 percent of sales; 57 percent of distribution passes through two doors.
This machine produces generic and licensed medicines, delivers them to pharmaceutical wholesalers, and deducts sales discounts and free-product incentives from revenue. Demand alone does not set the price. The Ministry of Health's reference exchange rate, public discount, and pricing policy reach all the way to the factory's sales label. DEVA may have 226 molecules in 441 formulations; its pricing power is not equally broad.
In the first three months of 2026, the Turkish pharmaceutical market grew 5.48 percent in boxes and 38.41 percent in TL. DEVA's IQVIA box sales rose 1.48 percent, while TL sales rose 29.10 percent. Its TL market share fell from 2.7 percent to 2.5 percent, and its ranking slipped from seventh to eighth. The company is not shrinking; the market is growing faster than it is. This is the first crack between management's phrase “giant pharmaceutical brands” and what is actually delivered to the shelf.
Exports open a more solid exit door. In the first quarter, exports totaled USD 18.4 million, or TL 802.6 million; this corresponds to approximately 13.6 percent of reported sales. Even so, exports are not yet large enough to make the local pricing machine irrelevant.
Profit is one thing, cash entering the till another
Sales rose 7.9 percent year on year to TL 5.91 billion. Gross margin fell from 37.2 percent to 35.1 percent, and operating margin from 8.2 percent to 5.9 percent. Operating profit declined 22.5 percent. The pharmacy shelf grew, while the share the factory kept from each lira of sales became smaller.
The net loss looks more dramatic than this operational erosion. DEVA generated TL 547.0 million in profit before tax; after TL 633.1 million in deferred tax expense, it reported a net loss of TL 90.9 million. The tax reconciliation includes a TL 417.6 million fixed-asset effect and a TL 166.5 million R&D deduction effect. The net loss is real, but it does not by itself describe the operating engine of 2026.
Cash is better, but tells a much weaker story than last year. Operating activities generated TL 1.47 billion in cash; purchases of tangible and intangible assets amounted to TL 796.6 million. Simple free cash flow is TL 675.5 million. In the same quarter of 2025, the same calculation was TL 3.95 billion.
| Period | Operating cash flow | Capital expenditure | Simple free cash flow |
|---|---|---|---|
| 1Q25 | 4.71 | 0.76 | 3.95 |
| 1Q26 | 1.47 | 0.80 | 0.68 |
Operating cash should not be polished too much either. The cash reconciliation includes TL 503.8 million of impairment, TL 637.9 million of tax, and a TL 1.00 billion provision adjustment. These add back to profit items that are either not cash outflows or belong to another period. The cash balance rejects the accounting loss, but it does not give the quality of profit a perfect score.
The ledger where licenses are written in and erased
DEVA's balance sheet contains TL 9.08 billion of intangible assets. Of this, TL 4.83 billion is net development cost and TL 4.20 billion is licenses and rights. The total equals 31.5 percent of equity. In the first quarter, TL 643.1 million of development costs were capitalized; the same cash flow reconciliation shows TL 463.7 million of impairment of intangible assets.
We do not know whether these two amounts relate to the same licenses. What we do know is more important: DEVA is carrying a significant portion of today's R&D cash into the future as an asset rather than an expense; it can also erase some of the values carried forward in the past. If a license succeeds, today's expense becomes tomorrow's sales. If the product fails to generate the expected cash, profit meets a cost that was deferred earlier.
The cheapness calculation here should be harsher than a dry price-to-book ratio. Subtracting all TL 9.08 billion of intangible assets from TL 28.84 billion of equity leaves TL 19.77 billion, or TL 98.82 per share. Removing 25 percent of inventories and 10 percent of trade receivables as well leaves TL 17.53 billion, or TL 87.66 per share. This is not a liquidation price. It is a resilience test that assigns no additional value to tangible fixed assets and does not account for a possible reversal of deferred tax liabilities.
| Scenario | Equity value | Value per share | Vs. current price |
|---|---|---|---|
| Reported equity | TRY 28.84bn | TRY 144.21 | +104.1% |
| All intangible assets written off | TRY 19.77bn | TRY 98.82 | +39.9% |
| Plus a 25% inventory and 10% receivables haircut | TRY 17.53bn | TRY 87.66 | +24.1% |
| Current market | TRY 14.13bn | TRY 70.65 | Reference |
At TL 70.65, the market is 19 percent below even this harsh calculation. The price is therefore not merely questioning the quality of the licenses. It is also punishing the cost of management, the controlling owner, distribution concentration, and the possibility that capital may turn toward the minority rather than serve it.
The price of control
EastPharma S.A.R.L. owns 82.2 percent of the shares. The company was established in Luxembourg in 2006; its owner is Bermuda-based EastPharma Ltd. In the first quarter, DEVA recorded TL 74.9 million in royalty expense payable to EastPharma, with TL 67.0 million owed at period-end. The footnote says that the royalty and license fee rates are based on a valuation by an independent institution authorized by the CMB. This is an important safeguard, but it does not change the economic reality: the minority investor depends both on the controlling owner and on certain rights held by that owner.
Debt is not an alarm, but a meter. Total financial debt is TL 6.67 billion; TL 4.52 billion is due within one year. After deducting cash and financial investments, net debt is TL 2.01 billion. The effective interest rate on short-term TL borrowing is 41.68 percent; the bonds carry 90 to 175 basis points over TLREF. DEVA is not in a liquidity crisis, but while gross margin is falling, the price of money is high.
Old bills are on the table too. Other short-term provisions under Note 18 total TL 1.09 billion. The company has set aside TL 117.6 million for 383 lawsuits. Total guarantees, pledges, and mortgages amount to TL 912.5 million, including TL 828.3 million in guarantees issued for ordinary commercial debts of third parties. These do not destroy equity on their own; they explain why the margin of safety should begin with a 49 percent discount to book value.
Four point seven times the first quarter
Of the TL 6.67 billion of debt on the 31 March balance sheet, deducting TL 3.77 billion of cash and TL 893.5 million of financial investments leaves net debt of TL 2.01 billion. Adding the TL 14.13 billion market capitalization produces an enterprise value of TL 16.14 billion.
The company does not disclose EBITDA. I therefore use a simple EBITDA proxy of TL 860.7 million, adding TL 512.8 million of depreciation and amortization from the financial statement cash flow to TL 347.9 million of operating profit. Multiplying this by four is not a forecast; it is the current price measured against first-quarter conditions. The mechanical annualized figure is TL 3.44 billion, making enterprise value 4.69 times that amount.
A 5.0x multiple produces a share value of TL 76.03, 6.0x produces TL 93.24, and 7.0x produces TL 110.46. The middle scenario, 6.0x, is not exuberant for a pharmaceutical company carrying a 5.9 percent operating margin, market-share loss, and a governance discount. Even so, multiplying the first quarter by four can conceal seasonality and the TMS 29 measurement date; this is why the table is sensitivity, not a target price.
| Case | Value per share |
|---|---|
| Current | TRY 70.65 |
| 5.0x | TRY 76.03 |
| 6.0x | TRY 93.24 |
| 7.0x | TRY 110.46 |
Two roads arrive in the same neighborhood. The harsh equity calculation gives TL 87.66, while the simple 6.0x EBITDA calculation gives TL 93.24. One attacks balance-sheet quality, the other operating strength. Both remain above TL 70.65. My verdict is therefore Cheap, not because the risks have disappeared, but because the price has already written them down several times.
Where the cheapness breaks
The bull case must be proved by four measures, not words: TL market share must move back toward 2.7 percent; operating margin must return to at least 8 percent; operating cash must cover investment by more than two times; and impairment of licenses must fall clearly relative to new capitalized development. If these occur, a 6.0x multiple begins to look like a floor.
The bear case is strong. Nearly one third of book value consists of licenses and development costs. The market is growing faster than DEVA. Two wholesalers carry 57 percent of sales. Management benefits equal 82 percent of operating profit. The controlling owner is not required to distribute capital. Annualizing the first quarter can create false confidence. In that case, 0.49x is not a penalty; it is the bill for whom and what the company spends its capital on.
I would reopen the verdict if two breaks appeared together in the next report: TL market share falling below 2.4 percent; free cash flow turning negative; intangible-asset impairment exceeding 75 percent of new capitalized development; net debt exceeding TL 3.5 billion; senior management benefits exceeding operating profit; or related-party terms expanding against the minority.
This share is not for the investor looking for a flawless company. It is for the investor who reads the control discount, license accounting, and regulated pricing, and searches for a margin of safety in the balance sheet. Owning DEVA means partnering not with the medicine on the pharmacy shelf, but with the money left between that medicine's license ledger and the executive floor.